Efficacy of voglibose in type 2 diabetes

Bibliography

• Scheen AJ. Is there a role for alpha-glucosidase inhibitors in the prevention of type 2 diabetes mellitus? Drugs 2003;63(10):933-51
   PubMed Web of Science ®Google Scholar
• Israili ZH. Advances in the treatment of type 2 diabetes mellitus. Am J Ther 2011;18(2):117-52
   Google Scholar
• International Diabetes Federation. 2011 Guideline for management of postmeal glucose in diabetes. International Diabetes Federation, Brussels. 2011. Available from: www.idf.org/sites/default/files/postmeal%20glucose%20guidelines.pdf [Accessed 25 February 2014]
   Google Scholar
• International Diabetes Federation. Diabetes facts and figures. 2013. Available from: www.idf.org/worlddiabetesday/toolkit/gp/facts-figures [Accessed 25 February 2014]
   Google Scholar
• Japanese Health Service Bureau of Ministry of Health, Labor and Welfare: 2012 Diabetes Mellitus Survey Report; 2013
   Google Scholar
• Choudhary N, Kalra S, Unnikrishnan AG, Ajish TP. Preventive pharmacotherapy in type 2 diabetes mellitus. Indian J Endocrinol Metab 2012;16(1):33-43
   Google Scholar
• DECODE Study Group, the European Diabetes Epidemiology Group. Glucose tolerance and cardiovascular mortality: comparison of fasting and 2-hour diagnostic criteria. Arch Intern Med 2001;161(3):397-405
   PubMedGoogle Scholar
• Coutinho M, Gerstein HC, Wang Y, Yusuf S. The relationship between glucose and incident cardiovascular events. A metaregression analysis of published data from 20 studies of 95,783 individuals followed for 12.4 years. Diabetes Care 1999;22(2):233-40
   PubMed Web of Science ®Google Scholar
• Ceriello A, Colagiuri S, Gerich J, Tuomilehto J; Guideline Development Group. Guideline for management of postmeal glucose. Nutr Metab Cardiovasc Dis 2008;18(4):S17-33
   Web of Science ®Google Scholar
• Gavin JR III. Pathophysiologic mechanisms of postprandial hyperglycemia. Am J Cardiol 2001;88(6A):4H-8H
   Google Scholar
• Japan Diabetes Society, editor. Evidence-based practice guideline for the treatment of diabetes in Japan, 2013. Nankodo, Tokyo; 2013
   Google Scholar
• Standl E, Schnell O. Alpha-glucosidase inhibitors 2012 – cardiovascular considerations and trial evaluation. Diab Vasc Dis Res 2012;9(3):163-9
   PubMed Web of Science ®Google Scholar
• Chen X, Zheng Y, Shen Y. Voglibose (Basen, AO-128), one of the most important alpha-glucosidase inhibitors. Curr Med Chem 2006;13(1):109-16
   Google Scholar
• Mooradian AD, Thurman JE. Drug therapy of postprandial hyperglycaemia. Drugs 1999;57(1):19-29
   Google Scholar
• Derosa G, Maffioli P. Alpha-glucosidase inhibitors and their use in clinical practice. Arch Med Sci 2012;8(5):899-906
   PubMed Web of Science ®Google Scholar
• Vichayanrat A, Ploybutr S, Tunlakit M, Watanakejorn P. Efficacy and safety of voglibose in comparison with acarbose in type 2 diabetic patients. Diabetes Res Clin Pract 2002;55(2):99-103
   PubMed Web of Science ®Google Scholar
• Abe M, Kikuchi F, Kaizu K, Matsumoto K. Combination therapy of pioglitazone with voglibose improves glycemic control safely and rapidly in Japanese type 2-diabetic patients on hemodialysis. Clin Nephrol 2007;68(5):287-94
   PubMed Web of Science ®Google Scholar
• Abe M, Okada K, Maruyama T, et al. Combination therapy with mitiglinide and voglibose improves glycemic control in type 2 diabetic patients on hemodialysis. Expert Opin Pharmacother 2010;11(2):169-76
   PubMed Web of Science ®Google Scholar
• Voglibose dispersible tablets. Summary of Product Characteristics. Available from: www.biocon.com/docs/prescribing_information/diabetology/volicose_pi.pdf [Accessed 14 February 2014]
   Google Scholar
• Fuder H, Kleist P, Birkel M, et al. The alpha-glucosidase inhibitor voglibose (AO-128) does not change pharmacodynamics or pharmacokinetics of warfarin. Eur J Clin Pharmacol 1997;53(2):153-7
   Google Scholar
• Kleist P, Suzuki Y, Thomsen T, et al. Voglibose has no effect on the pharmacokinetics of hydrochlorothiazide. Eur J Clin Pharmacol 1998;54(3):273-4
   Google Scholar
• Kusumoto M, Ueno K, Fujimura Y, et al. Lack of kinetic interaction between digoxin and voglibose. Eur J Clin Pharmacol 1999;55(1):79-80
   Google Scholar
• Kleist P, Ehrlich A, Suzuki Y, et al. Concomitant administration of the alpha-glucosidase inhibitor voglibose (AO-128) does not alter the pharmacokinetics of glibenclamide. Eur J Clin Pharmacol 1997;53(2):149-52
   Google Scholar
• Imamura A, Kusunoki M, Ueda S, et al. Impact of voglibose on the pharmacokinetics of dapagliflozin in Japanese patients with type 2 diabetes. Diabetes Ther 2013;4(1):41-9
   Google Scholar
• Yamaguchi M, Saji T, Mita S, et al. Pharmacokinetic and pharmacodynamic interaction of vildagliptin and voglibose in Japanese patients with type 2 diabetes. Int J Clin Pharmacol Ther 2013;51(8):641-51
   Google Scholar
• Göke B, Fuder H, Wieckhorst G, et al. Voglibose (AO-128) is an efficient alpha-glucosidase inhibitor and mobilizes the endogenous GLP-1 reserve. Digestion 1995;56(6):493-501
   Google Scholar
• Narita T, Yokoyama H, Yamashita R, et al. Comparisons of the effects of 12-week administration of miglitol and voglibose on the responses of plasma incretins after a mixed meal in Japanese type 2 diabetic patients. Diabetes Obes Metab 2012;14(3):283-7
   Google Scholar
• Kageyama S, Nakamichi N, Sekino H, Nakano S. Comparison of the effects of acarbose and voglibose in healthy subjects. Clin Ther 1997;19(4):720-9
   PubMed Web of Science ®Google Scholar
• Matsumoto K, Yano M, Miyake S, et al. Effects of voglibose on glycemic excursions, insulin secretion, and insulin sensitivity in non-insulin-treated NIDDM patients. Diabetes Care 1998;21(2):256-60
   Google Scholar
• Negishi M, Shimomura K, Proks P, et al. Alpha glucosidase inhibitor voglibose can prevent pioglitazone-induced body weight gain in type 2 diabetic patients. Br J Clin Pharmacol 2008;66(2):318-19
   Google Scholar
• Satoh N, Shimatsu A, Yamada K, et al. An alpha-glucosidase inhibitor, voglibose, reduces oxidative stress markers and soluble intercellular adhesion molecule 1 in obese type 2 diabetic patients. Metabolism 2006;55(6):786-93
   Google Scholar
• Shai I, Pischon T, Hu FB, et al. Soluble intercellular adhesion molecules, soluble vascular cell adhesion molecules, and risk of coronary heart disease. Obesity (Silver Spring) 2006;14(11):2099-106
   Google Scholar
• Ridker PM, Hennekens CH, Roitman-Johnson B, et al. Plasma concentration of soluble intercellular adhesion molecule 1 and risks of future myocardial infarction in apparently healthy men. Lancet 1998;351(9096):88-92
   PubMed Web of Science ®Google Scholar
• Seo C, Sakamoto M, Nishimura R, et al. Comparison of glycemic variability in patients with type 2 diabetes given sitagliptin or voglibose: a continuous glucose monitoring-based pilot study. Diabetes Technol Ther 2013;15(5):378-85
   Google Scholar
• Konya H, Katsuno T, Tsunoda T, et al. Effects of combination therapy with mitiglinide and voglibose on postprandial plasma glucose in patients with type 2 diabetes mellitus. Diabetes Metab Syndr Obes 2013;6:317-25
   Google Scholar
• Inoue M. Tighter control of postprandial hyperglycemia with mitiglinide/voglibose fixed-dose combination in Japanese patients with type 2 diabetes mellitus. Expert Opin Pharmacother 2012;13(16):2257-68
   PubMed Web of Science ®Google Scholar
• Ono Y, Kameda H, Cho KY. Mitiglinide/voglibose fixed-dose combination improves postprandial glycemic excursions in Japanese patients with type 2 diabetes mellitus. Expert Opin Pharmacother 2013;14(4):361-70
   PubMed Web of Science ®Google Scholar
• Ono Y, Nakamura A, Yong Cho K, Nomoto H. The glycemic/metabolic responses to meal tolerance tests at breakfast, lunch and dinner, and effects of the mitiglinide/voglibose fixed-dose combination on postprandial profiles in Japanese patients with type 2 diabetes mellitus. Expert Opin Pharmacother 2014;15(3):311-24
   PubMed Web of Science ®Google Scholar
• Ohta A, Ohshige T, Sakai K, et al. Comparison of the hypoglycemic effect of sitagliptin versus the combination of mitiglinide and voglibose in drug-naïve Japanese patients with type 2 diabetes. Expert Opin Pharmacother 2013;14(17):2315-22
   PubMed Web of Science ®Google Scholar
• Kurebayashi S, Watada H, Tanaka Y, et al. Efficacy and adverse effects of nateglinide in early type 2 diabetes. Comparison with voglibose in a cross-over study. Endocr J 2006;53(2):213-17
   Google Scholar
• Seino Y, Fujita T, Hiroi S, et al. Alogliptin plus voglibose in Japanese patients with type 2 diabetes: a randomized, double-blind, placebo-controlled trial with an open-label, long-term extension. Curr Med Res Opin 2011;27(Suppl 3):21-9
   PubMed Web of Science ®Google Scholar
• Seino Y, Fujita T, Hiroi S, et al. Efficacy and safety of alogliptin in Japanese patients with type 2 diabetes mellitus: a randomized, double-blind, dose-ranging comparison with placebo, followed by a long-term extension study. Curr Med Res Opin 2011;27(9):1781-92
   PubMed Web of Science ®Google Scholar
• Kawamori R, Inagaki N, Araki E, et al. Linagliptin monotherapy provides superior glycaemic control versus placebo or voglibose with comparable safety in Japanese patients with type 2 diabetes: a randomized, placebo and active comparator-controlled, double-blind study. Diabetes Obes Metab 2012;14(4):348-57
   PubMed Web of Science ®Google Scholar
• Iwamoto Y, Tajima N, Kadowaki T, et al. Efficacy and safety of sitagliptin monotherapy compared with voglibose in Japanese patients with type 2 diabetes: a randomized, double-blind trial. Diabetes Obes Metab 2010;12(7):613-22
   PubMedGoogle Scholar
• Iwamoto Y, Kashiwagi A, Yamada N, et al. Efficacy and safety of vildagliptin and voglibose in Japanese patients with type 2 diabetes: a 12-week, randomized, double-blind, active-controlled study. Diabetes Obes Metab 2010;12(8):700-8
   Google Scholar
• Kawamori R, Tajima N, Iwamoto Y, et al. Voglibose for prevention of type 2 diabetes mellitus: a randomised, double-blind trial in Japanese individuals with impaired glucose tolerance. Lancet 2009;373(9675):1607-14
   PubMed Web of Science ®Google Scholar
• Kawamori R, Tajima N, Iwamoto Y, et al. Predictive values of serum insulin kinetics for reversion of impaired glucose tolerance to normal glucose tolerance and the effects of voglibose treatment: a retrospective post hoc analysis of a Japanese phase III study. Diabetol Int 2012;3:209-16
   Google Scholar
• Lee MY, Choi DS, Lee MK, et al. Comparison of acarbose and voglibose in diabetes patients who are inadequately controlled with basal insulin treatment: randomized, parallel, open-label, active-controlled study. J Korean Med Sci 2014;29(1):90-7
   Google Scholar
• Kimura T, Suzuki J, Ichikawa M, et al. Differential effects of α-glucosidase inhibitors on postprandial plasma glucose and lipid profile in patients with type 2 diabetes under control with insulin lispro mix 50/50. Diabetes Technol Ther 2012;14(7):545-51
   PubMed Web of Science ®Google Scholar
• Yale JF. Oral antihyperglycemic agents and renal disease: new agents, new concepts. J Am Soc Nephrol 2005;16:7-10
   PubMedGoogle Scholar
• Kataoka Y, Yasuda S, Miyamoto Y, et al. Effects of voglibose and nateglinide on glycemic status and coronary atherosclerosis in early-stage diabetic patients. Circ J 2012;76(3):712-20
   Google Scholar
• Kataoka Y, Yasuda S, Miyamoto Y, et al. Clinical predictors of atheroma progression despite optimal glycemic control in early-stage diabetic patients with coronary artery disease: insight from the DIANA study. J Atheroscler Thromb 2014. [Epub ahead of print]
   Google Scholar
• Emoto T, Sawada T, Hashimoto M, et al. Effect of 3-month repeated administration of miglitol on vascular endothelial function in patients with diabetes mellitus and coronary artery disease. Am J Cardiol 2012;109(1):42-6
   Google Scholar
• Fujitaka K, Otani H, Jo F, et al. Comparison of metabolic profile and adiponectin level with pioglitazone versus voglibose in patients with type-2 diabetes mellitus associated with metabolic syndrome. Endocr J 2011;58(6):425-32
   Google Scholar
• Tsujimoto T, Shioyama E, Moriya K, et al. Pneumatosis cystoides intestinalis following alpha-glucosidase inhibitor treatment: a case report and review of the literature. World J Gastroenterol 2008;14(39):6087-92
   Google Scholar
• Intestinal alpha-glucosidase inhibitors: abdominal gas cysts. Prescrire Int 2012;21(130):212-13
   Google Scholar
• Nathan DM, Buse JB, Davidson MB, et al. Medical management of hyperglycemia in type 2 diabetes: a consensus algorithm for the initiation and adjustment of therapy: a consensus statement of the American Diabetes Association and the European Association for the Study of Diabetes. Diabetes Care 2009;32(1):193-203
   PubMed Web of Science ®Google Scholar
• Shimabukuro M, Masuzaki H, Sata M. Intensive glucose lowering in cardiovascular risk management - unsolved questions. Circ J 2012;76(3):593-5
   Google Scholar
• Chiasson JL, Josse RG, Gomis R, et al. Acarbose treatment and the risk of cardiovascular disease and hypertension in patients with impaired glucose tolerance: the STOP-NIDDM trial. JAMA 2003;290(4):486-94
   PubMed Web of Science ®Google Scholar
• Chiasson JL, Josse RG, Gomis R, et al. Acarbose for prevention of type 2 diabetes mellitus: the STOP-NIDDM randomised trial. Lancet 2002;359(9323):2072-7
   PubMed Web of Science ®Google Scholar
• Kolovou GD, Mikhailidis DP, Kovar J, et al. Assessment and clinical relevance of non-fasting and postprandial triglycerides: an expert panel statement. Curr Vasc Pharmacol 2011;9(3):258-70
   PubMed Web of Science ®Google Scholar